{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:46:05Z","timestamp":1791377165920,"version":"4.3.2"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004242","name":"Princess Nourah Bint Abdulrahman University","doi-asserted-by":"publisher","award":["PNURSP2025R116"],"award-info":[{"award-number":["PNURSP2025R116"]}],"id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from\n                      <jats:italic>Streptomyces<\/jats:italic>\n                      sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine\u2019s binding mode within the DNA\u2013Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via\n                      <jats:italic>in vitro<\/jats:italic>\n                      enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      aotaphenazine demonstrated a docking binding energy of \u201319.12 kcal\/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of \u201329.81 kcal\/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent \u03c0-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC\n                      <jats:sub>50<\/jats:sub>\n                      of 45.01\u2009nM, comparable to doxorubicin (30.16\u2009nM).\n                      <jats:italic>In vitro<\/jats:italic>\n                      cytotoxicity analysis revealed moderate activity across cancer cell lines (IC\n                      <jats:sub>50<\/jats:sub>\n                      \u2009=\u200926.30\u201354.35 \u00b5M) and significantly reduced toxicity in normal WI-38 and WISH cells (IC\n                      <jats:sub>50<\/jats:sub>\n                      \u2009=\u200969.86 \u00b5M and 84.72 \u00b5M, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2\/M population in MDA-MB-231 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0338135","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:38:46Z","timestamp":1764959926000},"page":"e0338135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aotaphenazine, a rare hydrophenazine, targets topoisomerase II with anticancer efficacy: In silico to in vitro evidence"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-1980","authenticated-orcid":true,"given":"Ahmed M.","family":"Metwaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael M.","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam B.","family":"Elkaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha A.","family":"Alsfouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"5","key":"pone.0338135.ref001","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CEJ.0000000000000594","article-title":"Progress in cancer mortality, incidence, and survival: a global overview","volume":"29","author":"C Santucci","year":"2020","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"pone.0338135.ref002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1389203724666230512144011","article-title":"Mechanism-based suppression of cancer by targeting DNA-replicating enzymes","volume":"25","author":"P Arya","year":"2024","journal-title":"Curr Protein Pept Sci"},{"issue":"5","key":"pone.0338135.ref003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"JL Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"pone.0338135.ref004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"JL Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"pone.0338135.ref005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2019.1621292","article-title":"Topoisomerase II inhibitors in AML: past, present, and future","volume":"20","author":"MP Economides","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"pone.0338135.ref006","article-title":"Prospects of topoisomerase inhibitors as promising anti-cancer agents","volume":"16","author":"PA Yakkala","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"pone.0338135.ref007","first-page":"111","article-title":"Cardiotoxicity of Anthracyclines","volume":"43","author":"E Balough","year":"2025","journal-title":"Cardiol Clin"},{"key":"pone.0338135.ref008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0378-4274(00)00192-2","article-title":"Genotoxicity of several clinically used topoisomerase II inhibitors","volume":"116","author":"G Boos","year":"2000","journal-title":"Toxicol Lett"},{"key":"pone.0338135.ref009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphar.2013.00089","article-title":"Mechanisms regulating resistance to inhibitors of topoisomerase II","volume":"4","author":"RN Ganapathi","year":"2013","journal-title":"Front Pharmacol"},{"key":"pone.0338135.ref010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-4781(98)00141-9","article-title":"Clinical resistance to topoisomerase-targeted drugs","volume":"1400","author":"AM Dingemans","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"pone.0338135.ref011","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1002\/ptr.7099","article-title":"Natural products: A lead for drug discovery and development","volume":"35","author":"B Chopra","year":"2021","journal-title":"Phytother Res"},{"issue":"19","key":"pone.0338135.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29194771","article-title":"Recent advances in phenazine natural products: chemical structures and biological activities","volume":"29","author":"W Huang","year":"2024","journal-title":"Molecules"},{"issue":"22","key":"pone.0338135.ref013","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1016\/j.bmc.2017.01.002","article-title":"Recent developments in the isolation, biological function, biosynthesis, and synthesis of phenazine natural products","volume":"25","author":"N Guttenberger","year":"2017","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"pone.0338135.ref014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/md19110610","article-title":"Advances in Phenazines over the Past Decade: Review of Their Pharmacological Activities, Mechanisms of Action, Biosynthetic Pathways and Synthetic Strategies","volume":"19","author":"J Yan","year":"2021","journal-title":"Mar Drugs"},{"issue":"4","key":"pone.0338135.ref015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1039\/c2np00079b","article-title":"Phenazines and cancer","volume":"29","author":"A Cimmino","year":"2012","journal-title":"Nat Prod Rep"},{"issue":"9","key":"pone.0338135.ref016","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1517\/17425255.2010.496251","article-title":"Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling","volume":"6","author":"JH Sung","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"pone.0338135.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312866","article-title":"Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays","volume":"19","author":"AM Metwaly","year":"2024","journal-title":"PLoS One"},{"issue":"29","key":"pone.0338135.ref018","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.2174\/0109298673339634241210151734","article-title":"Integrated in Silico and in Vitro Studies of Rutin\u2019s Potential against SARS-CoV-2 through the Inhibition of the RNA-dependent RNA Polymerase","volume":"32","author":"AM Metwaly","year":"2025","journal-title":"Curr Med Chem"},{"key":"pone.0338135.ref019","doi-asserted-by":"crossref","first-page":"138424","DOI":"10.1016\/j.molstruc.2024.138424","article-title":"Comprehensive structural and functional analysis of Patuletin as a potent inhibitor of SARS-CoV-2 targeting the RNA-dependent RNA polymerases","volume":"1311","author":"AM Metwaly","year":"2024","journal-title":"J Molecular Structure"},{"key":"pone.0338135.ref020","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16826","article-title":"In silico and in vitro evaluation of the anti-virulence potential of patuletin, a natural methoxy flavone, against Pseudomonas aeruginosa","volume":"12","author":"A Metwaly","year":"2024","journal-title":"PeerJ"},{"issue":"2","key":"pone.0338135.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24075","article-title":"Anti-virulence potential of patuletin, a natural flavone, against Staphylococcus aureus: In vitro and In silico investigations","volume":"10","author":"AM Metwaly","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"pone.0338135.ref022","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1080\/14756366.2022.2110868","article-title":"Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies","volume":"37","author":"RG Yousef","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"18","key":"pone.0338135.ref023","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.3390\/molecules27185859","article-title":"New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies","volume":"27","author":"EB Elkaeed","year":"2022","journal-title":"Molecules"},{"key":"pone.0338135.ref024","doi-asserted-by":"crossref","first-page":"136336","DOI":"10.1016\/j.molstruc.2023.136336","article-title":"New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story","volume":"1294","author":"IH Eissa","year":"2023","journal-title":"J Molecular Structure"},{"issue":"25","key":"pone.0338135.ref025","article-title":"Innovative nicotinamide-dihydrothiadiazole compounds for targeting VEGFR-2: design, synthesis, and mechanistic exploration in breast cancer treatment","volume":"10","author":"AM Metwaly","year":"2025","journal-title":"Chem Select"},{"key":"pone.0338135.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0113852728283226231227061211","article-title":"Nicotinamide loaded chitosan nanocomplex shows improved anticancer potential: molecular docking, synthesis, characterization and In Vitro evaluations","volume":"28","author":"M Metwaly","year":"2024","journal-title":"Current Organic Chemistry"},{"key":"pone.0338135.ref027","unstructured":"Metwaly AM, Abd-El-Azim H, Zewail M, Alsfouk AA, Elkaeed EB, Eissa IH. Chitosomal encapsulation enhances the anticancer efficacy of a theobromine analogue: an integrated in silico and in vitro study. 0(0):1\u201317."},{"key":"pone.0338135.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/6684015","article-title":"Preparation and characterization of patuletin-loaded chitosan nanoparticles with improved selectivity and safety profiles for anticancer applications","volume":"2023","author":"AM Metwaly","year":"2023","journal-title":"J Chemistry"},{"issue":"7","key":"pone.0338135.ref029","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1248\/cpb.c16-00038","article-title":"Bioactive secondary metabolites with unique aromatic and heterocyclic structures obtained from terrestrial actinomycetes species","volume":"64","author":"MS Abdelfattah","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"6","key":"pone.0338135.ref030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ja.2015.129","article-title":"New phenazine analogues from Streptomyces sp. IFM 11694 with TRAIL resistance-overcoming activities","volume":"69","author":"MS Abdelfattah","year":"2016","journal-title":"J Antibiot (Tokyo)"},{"key":"pone.0338135.ref031","doi-asserted-by":"crossref","unstructured":"Abdelfattah MS, Eissa IH, Mostafa AE, Elkaeed EB, Alsfouk AA, Mahmoud AA, et al. Resistomycin as a DNA-targeted topoisomerase II inhibitor: computational and mechanistic insights into its anticancer potential. 2025;49(5):17475198251385678.","DOI":"10.1177\/17475198251385678"},{"issue":"3","key":"pone.0338135.ref032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"GM Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"pone.0338135.ref033","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.1016\/j.dib.2021.106948","article-title":"Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS","volume":"35","author":"J Loschwitz","year":"2021","journal-title":"Data Brief"},{"issue":"10","key":"pone.0338135.ref034","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"BR Brooks","year":"2009","journal-title":"J Comput Chem"},{"issue":"6","key":"pone.0338135.ref035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10822-021-00389-3","article-title":"Improving virtual screening results with MM\/GBSA and MM\/PBSA rescoring","volume":"35","author":"H Sahakyan","year":"2021","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"pone.0338135.ref036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13321-021-00548-6","article-title":"ProLIF: a library to encode molecular interactions as fingerprints","volume":"13","author":"C Bouysset","year":"2021","journal-title":"J Cheminform"},{"key":"pone.0338135.ref037","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"S Salentin","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"pone.0338135.ref038","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1248\/cpb.c16-00038","article-title":"Bioactive secondary metabolites with unique aromatic and heterocyclic structures obtained from terrestrial actinomycetes species","volume":"64","author":"MS Abdelfattah","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"10","key":"pone.0338135.ref039","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.250","article-title":"Topoisomerase assays","volume":"1","author":"JL Nitiss","year":"2021","journal-title":"Curr Protoc"},{"key":"pone.0338135.ref040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1006\/clin.1995.1125","article-title":"Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides","volume":"76","author":"M Kuwana","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"pone.0338135.ref041","first-page":"137","article-title":"MTT assays","volume":"43","author":"R Supino","year":"1995","journal-title":"Methods Mol Biol"},{"key":"pone.0338135.ref042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"T Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"pone.0338135.ref043","volume-title":"Seminars in hematology","author":"Z Darzynkiewicz","year":"2001"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:38:55Z","timestamp":1764959935000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338135"}},"subtitle":[],"editor":[{"given":"Abdullahi Ibrahim","family":"Uba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}